INTRODUCTION
The zinc gradient across the plasma membrane may reach six orders of magnitude, as cytoplasmic Zn 2+ is tightly buffered by a variety of mechanisms (1 -channels leading to cell death (7, 8) . Chelation of intracellular Zn 2+ then, using a high affinity Zn 2+ chelator, could interfere with this process. Chelation of intracellular Zn 2+ , however, may remove zinc from intracellular metalloproteins, resulting in protein synthesis-dependent, caspase-3 mediated apoptosis (9) .
To protect cells from the consequences of a decrease in cellular zinc, changes in plasma Zn 2+ often precede the reduction of this ion within cells. Symptoms of zinc deficiency, therefore, particularly attenuation of cell proliferation, are observed long before changes in intracellular zinc are observed (10) . Thus, sensing changes in extracellular Zn 2+ , and activation of signaling to regulate cell processes, before key components (e.g., zinc finger proteins) are affected, is essential. This Zn 2+ -sensing function might also provide protection against a sudden rise in intracellular Zn 2+ in tissues in which Zn 2+ is released during normal activity, e.g., in endocrine and exocrine glands or at glutamatergic synapses in the mammalian forebrain. Extracellular Zn 2+ indirectly activates cell signaling, by interacting with major membrane transporters and ion channels, most notably, the dopamine transporter, NMDA, glycine, GABA, and purinergic receptors (11) (12) (13) (14) (15) . A high affinity binding site has also been (24) and enhances the recovery from acidic pH (29) . Once thought to merely regulate pHi, this Na + /H + exchanger is now believed to be involved in a much broader range of activities, particularly in regulation of cell proliferation and apoptosis (30) (31) (32) . Butyrate, a short chain fatty acid produced by bacterial fermentation in the colon, induces apoptosis of colonocytes and has been implicated in ulcerative colon diseases (33) (34) (35) . Interestingly, it has been demonstrated that zinc confers protection in ulcerative colitis, though the mechanism is not known (36 -dependnet mechanism can reduce the acid load by activating the NHE1, but must activate an additional pathway to mediate Zn 2+ -dependent cell survival. One candidate is the pro-survival glycoprotein, clusterin (CLU) (also known as apolipoprotein J) (37) . Initial experiments have shown that activation of the ZnR signaling pathway leads to enhancement of clusterin expression. The level of expression, moreover, was enhanced further by application of zinc and butyrate, suggesting a synergistic mechanism. Considering the strong pro-survival effects of clusterin described in the colon (37, 8) , it is tempting to speculate that such a mechanism may underlie the protective effect of zinc in preventing butyrate-induced cell death. This may further suggest a role for ZnR in the etiology of colon cancer.
A PARACRINE ROLE FOR THE PUTATIVE ZnR
Paracrine effects of signaling molecules trigger intracellular signaling pathways in neighboring cells that do not express a specific receptor. We posit that paracrine effects are of particular importance for amplifying signaling mediated by endogenous zinc, especially in the skin where zinc is involved in wound healing via an unknown mechanism. Yet, zinc is released only in minute amounts following the infliction of a wound or other epithelial damage (39) . The release of intracellular Ca 2+ , such as that induced by the pathway triggered by ZnR activity, is a principle mediator of paracrine responses, and has been shown to induce the release of important agonists such as ATP D 1 3 ( 7 -8 ) 3 3 1 -3 -dependent manner (43) . Zinc is packaged in secretory granules of many exocrine glands, such as the salivary glands, and the pancreas (1). Although a specific role for salivary Zn 2+ is unknown, loss of taste and salivary secretion dysfunctions have been linked to zinc deficiency, suggesting that this ion plays an important role in salivary secretion (44, 45) . We have observed that Zn
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, acting via the ZnR pathway, mediates release of intracellular Ca 2+ in the HSY, ductal salivary gland cell line (parotid origin) (24) . The endogenous release of ATP and, thereby, activation of the P2Y purinergic, receptor is important for regulation of the ionic content, volume and pH of the salivary fluid (24) . We therefore studied the role of extracellular Zn 2+ in regulating ATP secretion in co-cultures of HSY and vascular smooth muscle cells that do not express a functional ZnR. Activation of the salivary-ZnR in HSY cells was followed by a rise in Ca 2+ in the vascular cells that was inhibited by the ATP scavenger, apyrase. Our results, therefore, indicate that a salivary-ZnR also acts paracrinically, i.e., by enhancing secretion of ATP, thereby linking zinc and the ZnR activity to key signaling pathways involved in salivary secretion (24) . Clearly this model may encompass other secreted molecules, and may, thereby, extend the ability of ZnR to activate intracellular signaling. It may be particularly relevant with regard to the role of ZnR in wound healing. Although zinc is well known to enhance wound healing, we have identified ZnR-dependent signaling on keratinocytes and not on the fibroblasts that play such an important role in this process (22 
CONCLUSIONS
Cell signaling triggered by the putative ZnR, and its profound role in mediating Zn 2+ -dependent signaling, supports our hypothesis that such a receptor is a major link between extracellular zinc and its physiological functions such as secretion, or cell proliferation, and survival (see Figure 1 ). The ZnR, as a putative member of the G-protein coupled receptor (GPCR) family, which represents two percent of the human genome but is a target for about 50 percent of current pharmaceutical compounds, is particularly attractive as a target candidate for therapeutic interventions (51) . At the very least, regulation of ZnR activation is likely to be of significant importance in wound healing, diarrhea, and salivary dysfunction. In each of these conditions, zinc is already used therapeutically, though development of more potent ligands to activate such a ZnR may prove beneficial. The simplicity of Zn 2+ as a ligand holds out the promise that effective zinc mimetics can be developed. Inhibiting the function of a ZnR, either by reducing ligand availability or by means of its desensitization, also may provide a novel and efficacious strategy for attenuating tumor progression. The availability of effective in vivo zinc chelators and carriers, e.g., clioquinol, may, moreover, suggest an effective approach toward this goal.
